Research Roundup

light bulb with gears
Debbie Rigby takes a look at the latest in research news Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure The EMPEROR-Reduced Trial compared empagliflozin (10 mg once daily) or placebo (in addition to recommended therapy) in 3730 patients with heart failure and an ejection fraction of 40% or less. Results show a lower risk

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ‘Very, very lengthy delay’ torpedoes unfair dismissal case
Next COVID-19 and conduct: social media warning